Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib versus doxorubicin + ifosfamide as postoperative adjuvant therapy for high-grade soft tissue sarcoma
ChiCTR1900025067Phase 2Not yet recruiting
- Sponsor
- Cancer Hospital of Guangxi Medical University
- Start
- Sep 2019
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of anlotinib, doxorubicin and ifosfamide in soft tissue sarcoma (STS) (2 arms), sponsored by Cancer Hospital of Guangxi Medical University. Primary endpoints: Disease-free survival, 1-year disease-free survival rate and 1 more. Planned start Sep 2019; status: not yet recruiting.
02
Drugs
anlotinibdoxorubicinifosfamide
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on ChiCTR1900025067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900025067.